Dr. Devora Lichtman, MD
Internal Medicine (Internal Medicine Physician)
At a glance
- Years since graduation
- 7
- In the NPI registry since
- 2019
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2019Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
OH license 35.144283
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $62.78 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.80 |
|---|---|
| Abiomed | $22.59 |
| Angiodynamics, Inc. | $17.39 |
| Food and Beverage | $62.78 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 2 companies. The companies reported $16,869 in research payments for these studies, mostly to the institutions running them.
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company · Approved for marketing · NCT05172700 - A phase 3 open-label, randomized study of LOXO-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naive mantle cell lymphoma (bruin MCL-321)
Eli Lilly and Company - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Eli Lilly and Company · Active, not recruiting · NCT04965493 - A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Active, not recruiting · NCT05869903 - A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05872620 - Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Eli Lilly and Company · Active, not recruiting · NCT04666038 - A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company · Completed · NCT06045221
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.